ARS Pharmaceuticals Stock

ars-pharma.comHealthcareFounded: 2015Funding to Date: $76.55MM

ARS pharmaceuticals is developing an intranasal epinephrine spray for patients at-risk of severe allergic reactions to food, medications and insect bites that could lead to anaphylaxis.

Register for Details

For more details on financing and valuation for ARS Pharmaceuticals, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for ARS Pharmaceuticals.

Register Today

Other companies like ARS Pharmaceuticals in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$885.01MM
Sector